2TZ Stock Chart & Stats
€2.72
>-€0.01(-0.15%)
At close: 4:00 PM EST
€2.72
>-€0.01(-0.15%)
Day’s Range― - ―
52-Week Range€2.04 - €3.15
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€3.22B
Enterprise Value€0.00
Total Cash (Recent Filing)€1.77B
Total Debt (Recent Filing)€53.47M
Price to Earnings (P/E)13.6
Beta0.05
Next Earnings
Aug 15, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)2.84
Shares Outstanding200,000,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio-1.92
Price to Book (P/B)2.58
Price to Sales (P/S)3.73
P/FCF Ratio53.57
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.18
Revenue Forecast (FY)€648.01M
Bulls Say, Bears Say
Bulls Say
Conservative Balance Sheet / Very Low LeverageMinimal debt and equity representing the bulk of assets provide sustained financial flexibility. Low leverage reduces refinancing/default risk, supports steady dividend or capex funding, and allows the company to pursue strategic investments or M&A without stressing cash flow over the medium term.
Very High And Sustainable MarginsExceptionally strong gross, operating and net margins indicate durable pricing power and efficient operations. These margins create a buffer against input cost volatility, enable reinvestment in product development and distribution, and help preserve profitability even if top-line growth softens.
Improving Free Cash Flow TrendSignificant FCF growth highlights strengthening cash generation capacity. Rising free cash flow supports longer-term funding for R&D, manufacturing, dividends or strategic initiatives and increases resilience versus cyclical downturns, improving long-run operational optionality.
Bears Say
Revenue Volatility And Recent DeclineMulti-year revenue volatility and recent declines undermine scale and predictability, complicating long-term planning. Fluctuating top-line reduces capacity to leverage fixed costs, may erode channel confidence, and raises uncertainty about sustainable demand for core products.
Weak Earnings-to-cash ConversionOperating cash flow materially below reported net income signals weak cash conversion and potential working-capital timing or accrual issues. If persistent, this gap jeopardizes the reliability of earnings to fund dividends, capex, or growth without tapping balance-sheet flexibility.
Balance-sheet Contraction / Asset DeclineA shrinking asset base may reflect lower inventories, disposals, or weaker operating scale. Balance-sheet contraction can limit production capacity and investment headroom, constraining revenue recovery and signaling potential structural demand or operational retrenchment risks.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S News
2TZ FAQ
What was Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price range in the past 12 months?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S lowest stock price was €2.04 and its highest was €3.15 in the past 12 months.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s market cap is €3.22B.
When is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s upcoming earnings report date is Aug 15, 2026 which is in 31 days.
How were Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s earnings last quarter?
Currently, no data Available
Is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S overvalued?
According to Wall Street analysts Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price is currently Overvalued.
Does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S pay dividends?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S does not currently pay dividends.
What is Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S have?
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S has 200,000,000 shares outstanding.
What happened to Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S?
Currently, no hedge funds are holding shares in DE:2TZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S Stock Smart Score
Company Description
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (TPDRTG), a prominent pharmaceutical group operating with its various subsidiaries, primarily serves the People's Republic of China. Its core focus lies in the production and sale of traditional Chinese medicines, Western pharmaceuticals, and health-related products. The company's operations are distinctly divided into two key segments: Chinese Medicine and Western Medicine. Beyond manufacturing, TPDRTG is actively involved in the development and commercialization of both traditional Chinese and Western pharmaceutical and biological items. It also maintains and operates hospitals, alongside running extensive wholesale and retail networks for various medicines, biochemical products, and everyday consumer goods. Furthermore, TPDRTG extends its operations to include a suite of services such as logistics, inventory management, equipment installation, specialized medicine processing, inspection and testing, and pharmaceutical consultancy. The company's commercial strategy involves both the direct supply of its proprietary branded medicinal products to wholesalers, and acting as an intermediary to distribute third-party medicinal products to other wholesalers. Established in 1992, the company was formerly known as Tianjin Zhong Xin Pharmaceutical Group Corporation Limited, adopting its current name in May 2022. It is headquartered in Tianjin, People's Republic of China.
Tianjin Zhongxin Pharmaceutical Group Corp. Ltd. Class S (2TZ) Earnings & Revenues
Technical Analysis
Hyphens Pharma International Ltd.
―
iX Biopharma Ltd.
―
Medtecs International Corporation Ltd.
―
Biolidics Ltd.
―
Pharmesis International Ltd.
―
Options Prices
Currently, No data available
---